Glutathione treatment in patients with ovarian cancer during AP combination chemotherapy
Автор: Abakumova T.V., Gening S.O., Fedotova A.Yu., Myasnikova D.F., Antoneeva I.I., Dolgova D.R., Gening T.P.
Журнал: Ульяновский медико-биологический журнал @medbio-ulsu
Рубрика: Клиническая медицина
Статья в выпуске: 2, 2018 года.
Бесплатный доступ
Ovarian cancer (OC) is highly sensitive to chemotherapy (CT). The chemotherapy effectiveness is reduced as a result of cytostatic clearance from tumor cells. The glutathione system provides cell resistance to platinum and anthracyclines. At the same time, the activation of reactive oxygen, leading to the onset of oxidative stress (OS), is an important component of the cytostatics antitumor effect. The glutathione system acts as an antioxidant mechanism blocking the OS pro-carcinogenic effect. The purpose of the study is to evaluate the glutathione system in blood plasma, erythrocytes and tumor tissue during neoadjuvant AP combination CT. Materials and Methods. Women with a verified OC were enrolled in the study. The patients were divided into two groups. Patients of the 1st group underwent neoadjuvant chemotherapy, the patients of the 2nd group received adjuvant AP combination chemotherapy. The activity of glutathione S-transferase (GST), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione (GSH) level were determined in plasma and erythrocytes of Group 1 patients, as well as in tumor and externally unchanged ovarian tissues obtained intraoperatively in both groups...
Ovarian cancer, chemotherapy, glutathione system
Короткий адрес: https://sciup.org/14113358
IDR: 14113358 | DOI: 10.23648/UMBJ.2018.30.14046